Kyle Mikson
Stock Analyst at Canaccord Genuity
(1.02)
# 3,656
Out of 4,920 analysts
85
Total ratings
26.76%
Success rate
-12.68%
Average return
Main Sectors:
Stocks Rated by Kyle Mikson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Maintains: Hold | $99 → $105 | $97.76 | +7.41% | 12 | Aug 1, 2025 | |
| XGN Exagen | Maintains: Buy | $8 → $11 | $8.87 | +24.01% | 4 | Jul 30, 2025 | |
| GRAL GRAIL | Maintains: Buy | $32 → $43 | $33.75 | +27.41% | 2 | May 14, 2025 | |
| BDSX Biodesix | Maintains: Buy | $2.5 → $1.5 | $0.42 | +254.61% | 4 | May 14, 2025 | |
| QTRX Quanterix | Maintains: Buy | $15 → $12 | $5.96 | +101.34% | 6 | May 13, 2025 | |
| TXG 10x Genomics | Maintains: Buy | $18 → $15 | $13.31 | +12.70% | 8 | May 12, 2025 | |
| CSTL Castle Biosciences | Maintains: Buy | $42 → $37 | $20.35 | +81.82% | 4 | May 6, 2025 | |
| GH Guardant Health | Maintains: Buy | $60 → $65 | $46.17 | +40.78% | 7 | May 1, 2025 | |
| RGEN Repligen | Maintains: Hold | $170 → $150 | $115.88 | +29.44% | 3 | Apr 16, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $3 | $1.42 | +111.27% | 8 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $195 | $140.12 | +39.17% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.00 | +200.00% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $1.5 → $1 | $1.44 | -30.56% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $75 | $47.36 | +58.36% | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $2 | $0.64 | +212.50% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $49 | $0.49 | +9,940.82% | 1 | Mar 30, 2021 |
Illumina
Aug 1, 2025
Maintains: Hold
Price Target: $99 → $105
Current: $97.76
Upside: +7.41%
Exagen
Jul 30, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $8.87
Upside: +24.01%
GRAIL
May 14, 2025
Maintains: Buy
Price Target: $32 → $43
Current: $33.75
Upside: +27.41%
Biodesix
May 14, 2025
Maintains: Buy
Price Target: $2.5 → $1.5
Current: $0.42
Upside: +254.61%
Quanterix
May 13, 2025
Maintains: Buy
Price Target: $15 → $12
Current: $5.96
Upside: +101.34%
10x Genomics
May 12, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $13.31
Upside: +12.70%
Castle Biosciences
May 6, 2025
Maintains: Buy
Price Target: $42 → $37
Current: $20.35
Upside: +81.82%
Guardant Health
May 1, 2025
Maintains: Buy
Price Target: $60 → $65
Current: $46.17
Upside: +40.78%
Repligen
Apr 16, 2025
Maintains: Hold
Price Target: $170 → $150
Current: $115.88
Upside: +29.44%
Pacific Biosciences of California
Apr 10, 2025
Maintains: Buy
Price Target: $3
Current: $1.42
Upside: +111.27%
Feb 28, 2025
Maintains: Buy
Price Target: $180 → $195
Current: $140.12
Upside: +39.17%
Nov 14, 2024
Maintains: Buy
Price Target: $3
Current: $1.00
Upside: +200.00%
Nov 13, 2024
Maintains: Hold
Price Target: $1.5 → $1
Current: $1.44
Upside: -30.56%
Nov 6, 2024
Maintains: Buy
Price Target: $95 → $75
Current: $47.36
Upside: +58.36%
Aug 16, 2023
Maintains: Overweight
Price Target: $3 → $2
Current: $0.64
Upside: +212.50%
Mar 30, 2021
Initiates: Overweight
Price Target: $49
Current: $0.49
Upside: +9,940.82%